Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2002
08/22/2002WO2002045652A3 Tyrosine kinase inhibitors
08/22/2002WO2002044159A3 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatment of incontinence
08/22/2002WO2002042280A3 Pyrimidine derivatives
08/22/2002WO2002040471A3 Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
08/22/2002WO2002040021A3 Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines
08/22/2002WO2002040008A3 Treatment of sexual dysfunction with non peptide bombesin receptor antagonists
08/22/2002WO2002038557A3 Benzoylbenzofurane derivatives for treatment of cardiac arrhythmia
08/22/2002WO2002036587A3 Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
08/22/2002WO2002033050A3 Methods and compositions for promoting the maturation of monocytes
08/22/2002WO2002032893A3 Piperidine compounds as anti-allergic
08/22/2002WO2002032869A3 Substituted heterocyclic compounds for treating multidrug resistance
08/22/2002WO2002032862A3 Use of p38 inhibitors for the treatment of smoke inhalation
08/22/2002WO2002032404A3 Nanoparticles
08/22/2002WO2002032377A3 Estrogen receptor modulators
08/22/2002WO2002026325A3 Restoration of perturbed barrier function by application of antiandrogens
08/22/2002WO2002024204A3 Treatment of diabetes mellitus by inhibition of mitochondrial calcium/sodium antiporter
08/22/2002WO2002024160A3 Long acting antidepressant microparticles
08/22/2002WO2002024002A3 Food supplement
08/22/2002WO2002022141A3 Xenon as medicament
08/22/2002WO2002019995A3 Pharmaceutical combination containing salmeterol and fluticasone
08/22/2002WO2002015959A3 Compounds and compositions for delivering active agents
08/22/2002WO2002004412A3 Tyrosine derivatives as phosphatase inhibitors
08/22/2002WO2001093850A3 Methods and compositions using sulodexide for the treatment of diabetic nephropathy
08/22/2002WO2001085013A3 Infrared thermography and methods of use
08/22/2002WO2001080842A3 Compositions comprising a methylnogarol in combination with an antiproliferative agent
08/22/2002WO2001070982A3 Brca-1 regulators and methods of use
08/22/2002WO2001070214A3 The use of cocoa procyanidins combined with acetylsalicyclic acid as an anti-platelet therapy
08/22/2002WO2000038706A9 Methods for treating cancer and for mediating chemotaxis of dendritic cells
08/22/2002WO2000035423A9 Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same
08/22/2002WO2000033979A9 Apparatus for separating particles of cohesive material according to size and process
08/22/2002WO2000032239A9 Hapten-carrier conjugates for treating and preventing nicotine addiction
08/22/2002WO2000011195A9 C-myc is activated by beta-catenin and tcf-4
08/22/2002WO1999063992A9 Novel calcium channel drugs and uses
08/22/2002US20020116724 Nucleotide sequences codingolypeptide for use in the diagnosis and prevention of psoriasis and venous ulcers
08/22/2002US20020116272 Advertising strategy and motivational behavior modification method for weight loss
08/22/2002US20020116000 Supplemental spine fixation device and method
08/22/2002US20020115858 Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
08/22/2002US20020115856 Selective cyclooxygenase-2 (COX-2) inhibitors; for example, 1-(5-Methanesulfonyl-pyridin-2-yl)-7-methoxy-3-trifluoromethyl-4,5-dihydro -1H-benzo(g)indazole
08/22/2002US20020115854 Thrombin or factor Xa inhibitors
08/22/2002US20020115853 6-(3-nitrophenyl)-3H-benzooxazol-2-one for example; contraceptives, treating hormone dependent tumors, endometriosis; progesterone receptor agonists and antagonists
08/22/2002US20020115835 Methods utilizing aryl thioimines in synthesis of erythromycin derivatives
08/22/2002US20020115829 Pathogenic escherichia coli associated protein
08/22/2002US20020115826 Enzyme inhibitor for use for use in the treatment of cell proliferative defects
08/22/2002US20020115728 Compositions and methods for treating cardiovascular disorders
08/22/2002US20020115727 Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines
08/22/2002US20020115726 Methods and compositions for treating depression and other disorders using optically pure (-) -bupropion
08/22/2002US20020115725 Methods and compositions for regulating memory consolidation
08/22/2002US20020115724 Methods and agents for inhibiting protein aging
08/22/2002US20020115722 Derivatives of 1-aryl-3-(2-chloroethyl)ureas having specific spatial configurations allowing these derivatives to dock inside cells at pre-selected sites.
08/22/2002US20020115720 Especially applying the retinoid to a contact lens and placing the contact lens in the eye.
08/22/2002US20020115719 Control of microbial populations in the gastrointestinal tract of animals
08/22/2002US20020115718 Divalproex sodium tablets
08/22/2002US20020115716 Oral low dose butyrate compositions
08/22/2002US20020115715 Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
08/22/2002US20020115714 Protein kinase inhibitor
08/22/2002US20020115713 Phenylarsine oxide or salts of aminophenyl- or isoxazole-arsine oxide are anti-thiol reagents that oxidize or block PDI active site vicinal thiol groups which normally participate in disulfide bond rearrangement of PDI substrates.
08/22/2002US20020115712 Highly purified simvastatin compositions
08/22/2002US20020115710 Composition and method
08/22/2002US20020115709 Atorvastatin hemi-calcium form VII
08/22/2002US20020115708 Antiestrogenic and antitumorigenic activities
08/22/2002US20020115706 Treatment of both hearing loss and loss of the sense of balance by administering a a fused pyrrolocarbazole derivative
08/22/2002US20020115705 Analgesic compositions comprising anti-epileptic compounds and methods of using same
08/22/2002US20020115704 Treatment method
08/22/2002US20020115703 Administering an alpha2-adrenoceptor antagonist or a pharmaceutically acceptable ester or salt thereof, such as atipamezole, analogs of idazoxan, and analogs of efaroxan.
08/22/2002US20020115702 Administering substituted imidazoles, particular by losartan potassium, treatment of post-transplant hypertension.
08/22/2002US20020115701 Have antipyretic action, analgesic action, antiinflammatory action, and particularly, selective inhibitory action on cyclooxygenase-2; ketomethylene intermediates
08/22/2002US20020115700 Inhibiting telomerase activity with 5-(3-Isatinylidinyl)thiazolidineones and 3-(thiazolidinon-5-yl) indoles
08/22/2002US20020115699 Method for treating renal disease
08/22/2002US20020115698 Selective inhibition of glutaminase by bis-thiadiazoles
08/22/2002US20020115697 Azabicyclic compounds used in treating a disease in the central nervous system caused by malfunctioning of the muscarinic cholinergic system.
08/22/2002US20020115696 Preferred are farnesylthiosalicyclic acid and its chloro- and fluoro- derivatives; 2-chloro-5-farnesylaminobenzoic acid; farnesylthionicoatinic acid; and farnesylmethylthiosalicylic acid.
08/22/2002US20020115695 Combinations of a prostaglandin agonist and a HMG-CoA reductase inhibitor
08/22/2002US20020115694 Methods for the treatment and prevention of urinary stone disease
08/22/2002US20020115691 S-rabeprazole compositions and methods
08/22/2002US20020115690 Free of alcohol and propylene glycol; surfactant; polyethylene glycol solvent having a mean molecular weight of greater than 300 but lower than 600
08/22/2002US20020115689 Combination therapy for treating neurodegenerative disease
08/22/2002US20020115688 Screen for glutamate reuptake inhibitors, stimulators, and modulators
08/22/2002US20020115687 An adenosine A1 antagonist, such as BG9719, and a non-adenosine modifying diuretic.
08/22/2002US20020115684 2, 7-naphthyridine derivatives
08/22/2002US20020115683 Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
08/22/2002US20020115682 Especially Alzheimer's disease; using hydrogenated pyrido (4,3-b) indole derivatives
08/22/2002US20020115681 Anticholinergics which have a long-lasting effect, such as glycopyrronium bromide, tiotropium bromide or an ester of bi-or tricyclic amino alcohol such as a nortropanol
08/22/2002US20020115679 N-acyl- or N-sulfonylpiperidine substituted tricyclic benzocycloheptenepyridine derivatives
08/22/2002US20020115678 Compounds, compositions and methods for treating antibiotic-resistant infections
08/22/2002US20020115677 Such as a combretastatin
08/22/2002US20020115676 Therapy for andropause using estrogen agonists / antagonists and testosterone
08/22/2002US20020115671 Inhibitors of p38-a kinase
08/22/2002US20020115670 1-Aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
08/22/2002US20020115668 Having HIV replication inhibiting properties.
08/22/2002US20020115667 Treatment of disorders associated with glycolipid accumulation, such as Niemann-Pick Type C disease by administering an inhibitor of glucosylceramide synthesis, such as N-butyldeoxynojirimycin
08/22/2002US20020115665 Contacting the calpain with an effective amount of an HIV protease inhibitor,
08/22/2002US20020115662 Delta-opioid or mu-opioid receptor modulators; useful analgesics, immunosuppressants, antiinflammatory agents, agents for the treatment of respiratory diseases.
08/22/2002US20020115661 Method for treating chronic obstructive pulmonary disease
08/22/2002US20020115658 Aniline disulfide derivatives for treating allergic diseases
08/22/2002US20020115656 Administering 2-(1-(3-(5-Acetyl-3-(4-chloro-phenyl)-4,5,6,7-tetrahydro-pyrazolo-(4,3 -c)pyridin-1-yl)-2-hydroxy-propyl)-piperidin-4-ylamino)-benzonitrile for inhibiting cathepsins; for treating atopic diseases
08/22/2002US20020115654 New compounds, their preparation and use
08/22/2002US20020115653 Retinoic acid mimetic anilides
08/22/2002US20020115652 Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
08/22/2002US20020115651 New hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and processes for their preparation
08/22/2002US20020115650 Cephalosporin antibiotics and prodrugs thereof